Coretag

People want to enjoy a longer life, and in good health. Celebrating the big and small moments – with family and friends – even when they become a patient. That’s why Coretag set itself goals to improve the diagnosis, monitoring and treatment of cancer. So that people can live longer and treatment times for cancer become shorter. Coretag focuses on the development of cancer imaging and targeted radiotherapy, based on its proprietary Necrosis Targeting Platform Technology (NTPT). Coretag has developed a portfolio of products that address high unmet needs in oncology. Coretag is preparing to be listed on the Nasdaq stock exchange in 2022. The NTPT was developed as a result of the discovery of a group of cyanine dyes which have selective targeting properties to intracellular proteins. These proteins become available for binding only when the cell membrane lost its integrity, which occurs once a cell has become necrotic. Necrosis appears in pathological conditions like a stroke, myocardial infarction, and osteoarthritis. Necrosis also appears in aggressively growing tumors, where cancer cells die due to the lack of oxygen, caused by a poor blood perfusion in the solid tumor or metastases. Coretag defined a pipeline for the development of cancer imaging and targeted radiotherapy, which is executed in close partnership with Prinicipal Investigators and medical hospitals. To further fulfil our ambitions, we are currently forming partnerships with oncologists, radiologists and nuclear specialists in the EU and USA.